Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has revolutionized the management of metastatic prostate cancer, significantly improving the detection of small-volume disease and guiding targeted therapies, such as Lu-177 PSMA-617 (LuPSMA) [1] for metastatic castration-resistant prostate cancer (mCRPC). The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.